TARGIT-IORT

TARGeted Intraoperative radiotherapy



Prof JS Tobias, Prof JS Vaidya, Prof M Bulsara, Prof M Baum

Jayant S Vaidya, Max Bulsara, Michael Baum, Frederik Wenz, Samuele Massarut, Steffi Pigorsch, Michael Alvarado, Michael Douek, Christobel Saunders, Henrik Flyger, Wolfgang Eiermann, Chris Brew-Graves, Norman Williams, Ingrid Potyka, Nicholas Roberts, Marcelle Bernstein, Douglas Brown, Elena Sperk, Siobhan Laws, Marc Sütterlin, Tammy Corica, Steinar Lundgren, Dennis Holmes, Lorenzo Vinante, Fernando Bozza, Montserrat Pazos, Magali Le Blanc-Onfroy, Günther Gruber, Wojciech Polkowski, Konstantin J Dedes, Marcus Niewald, Jens Blohmer, David McCready, Richard Hoefer, Pond Kelemen, Gloria Petralia, Mary Falzon, David Joseph, Jeffrey S Tobias.





Acknowledgements



International Steering Committee

Trial Steering Committee 2019



Jayant S Vaidya, Max Bulsara, Michael Baum, Frederik Wenz, Samuele Massarut, Steffi Pigorsch, Michael Alvarado, Michael Douek, Christobel Saunders, Henrik Flyger, Wolfgang Eiermann, Chris Brew-Graves, Norman Williams, Ingrid Potyka, Nicholas Roberts, Marcelle Bernstein, Douglas Brown, Elena Sperk, Siobhan Laws, Marc Sütterlin, Tammy Corica, Steinar Lundgren, Dennis Holmes, Lorenzo Vinante, Fernando Bozza, Montserrat Pazos, Magali Le Blanc-Onfroy, Günther Gruber, Wojciech Polkowski, Konstantin J Dedes, Marcus Niewald, Jens Blohmer, David McCready, Richard Hoefer, Pond Kelemen, Gloria Petralia, Mary Falzon, David Joseph, Jeffrey S Tobias.

The TARGIT-A trial investigators / authors

More info at targit.org.uk





Professor Max Bulsara

Potential conflict of Interest

- I receive grant funding for UCL from Dept of Health NIHR HTA
- I receive honoraria / travel reimbursement from Carl Zeiss





"Can you come to the hospital every day for 6 weeks for radiotherapy?" YES we can

YOU HAVE


BREAST CANCER




This presentation is the intellectual property of Jayant S Vaidya. Contact jayant.vaidya@ucl.ac.uk for permission to reprint and/or distribute

Concern about patients and curiosity about breast cancer


Whole organ analysis of mastectomy specimens





The breast has many other microscopic cancers BUT >90% recurrences occur in the index quadrant. Sensible to target radiotherapy just to the tumour bed

This presentation is the intellectual property of Jayant S Vaidya. Contact jayant.vaidya@ucl.ac.uk for permission to reprint and/or distribute



44.4

Multicentricity and its Influence on Conservative Breast Cancer Treatment Strategy.

Vaidya J S, Vyas J J, Mittra I, Chinoy F F Tata Memorial Hospital, Bombay, India

The guiding principle is local treatment of breast cancer, that the whole breast needs treatment, either by surgery alone or in combination with radiotherapy, is based on the presence of multicentricity. We studied multicentricity of breast cancer with special attention to its spatial relationship to the primary tumour.

30 breast specimens were studied using Egan's method. Briefly, the whole breast was frozen (-80°C) and cut into 5mm slices that were radiographed. Each greasly and radiographically suspicious facus was examined microscopically. Turnour radius and x, y and z co-ordinates of the turnour centre and that of each focus were measured. A focus showing hyperplasia with atypia, DCIS, IDC, LCIS er ILC was labelled as a positive tesion. Distance of each MCF from edge of turnour and percentage of total breast volume needing excision to include the farthest MCF were calculated.

A total of 667 blocks were studied, 19 cases had +ve foci. A total of 54 +ve MCF were found. There was no relationship between tumour size or nodal status and number, distance or type of MCF. We found that 15/30 patients would need excision of more than 25% of breast volume (or a quadrant) to include the farthest MCF from tumour edge. We found that while primary tumour was most common in the UOQ, MCF were scattered truer, all 4 punctants. The difference is between the UOQ, MCF were scattered


statistically significant (p=.02). Thus, our analyses revealed wide distribution of MCF in breast. Since most recurrences seen in large conservative surgery trials have occured near primary tumour, our results suggest that MCF are probably not the cause of recurrences and 1) achieving microscopically. free surgical margins and 2) delivery of external RT to treat MCF in the remaining breast might be both unnecessary. This could form the basis of a clinical trial to test whether giving RT to only the quadrant of primary tumour makes a difference in the incidence of local recurrence. Mastectomy with Immediate brea Dorsi flap only: Tata Memorial Ho


Vyas Jitendra J. Valdya Jayart 5. 5 Tata Memorial Hospital, Bombay, 4

The value of immediate breast rebreast cancer requires no emphasi deterrent in India for use of r transposition seemed more appromuscle without a silicone implant. The patients who had operable bre not desirous of conservative su reconstruction. Women of medium a reasonable amount of fat over selected. In locally advanced by neoadjuvant chemotherapy who have main aim was cover with vascula average age was 35 yrs. Sixty-fr Whole of the Latissimus dorsi mus amount of suboutaneous fat. The m initial complication rate of 20% dr period. The mean hospital stay y institution of adjuvant chemotherap of breakdown of posterior wound reducing the width of the skin pad excellent in 35%, good in 50%. 15% achieve symmetry. In 85% of patie not be discerned after wearing routithe reconstruction. The accrual rate with earlier patients or were shown t Immediate reconstruction with auto easy, expeditious and low cost met image in Indian women.

Concern about patients and curiosity about breast cancer

Whole organ analysis of mastectomy specimens





The breast has many other microscopic cancers BUT >90% recurrences occur in the index quadrant.

Sensible to target radiotherapy just to the tumour bed

Multicentricity and its Influence on Conservative Breast Cancer Treatment Strategy	M in
Vaidya J S, Vyas J J, Mittra I, Chinoy R F	JS
	Cancer Treatment Strategy.

Br J Cancer 1996;74:820-824

Multicentricity of breast cancer: whole-organ analysis and clinical implications

JS Vaidya', JJ Vyas', RF Chinoy², N Merchant³, OP Sharma³ and I Mittra'

THE LANCET

1997 Jan 18;349(9046):208


Multicentricity and recurrence of breast cancer

Michael Baum, *Jayant S Vaidya, Indraneel Mittra *Department of Surgery, Institute of Surgical Studies, University College London, London W1P 7LD, UK; and Department of Surgery, Tata Memorial Hospital, Bombay, India

This presentation is the intellectual property of Jayant S Vaidya. Contact jayant.vaidya@ucl.ac.uk for permission to reprint and/or distribute

ice of local recurrence.


The TARGIT technique









Most breast cancer treatment is completed by the surgeon!!







How to give intraoperative radiotherapy TARGIT-IORT








The TARGIT-IORT Technique Developed in UCL/Middlesex Hospital 1996-98



Choose the applicator (1.5 to 5cm) according to size of the patient's tumour bed

X-ray source and applicator





- Radiotherapy delivered immediately after lumpectomy
- Focused radiation to the tumour bed:
 - Targets tissues at highest risk of relapse
 - Avoids normal structures eg heart and lungs **PRECISION and IMMEDIACY**

The surgical technique

EJSO 2002; **28**: 447–454 doi:10.1053/ejso.2002.1275, available online at http://www.idealibrary.com on **IDE**



EDUCATIONAL SECTION

The novel technique of delivering targeted intraoperative radiotherapy (Targit) for early breast cancer

Jayant S. Vaidya, Michael Baum, Jeffrey S. Tobias*, Steven Morgan† and Derek D'Souza†

The first 25 patients' results

Annals of Oncology **12**: 1075–1080, 2001. © 2001 Kluwer Academic Publishers. Printed in the Netherlands.

Original article _____

*Targ*eted *i*ntra-operative radio*t*herapy (*Targit*): An innovative method of treatment for early breast cancer

J. S. Vaidya,¹ M. Baum,¹ J. S. Tobias,² D. P. D'Souza,³ S.V. Naidu³ S. Morgan,³ M. Metaxas,³ K. J. Harte,⁴ A. P. Sliski⁴ & E. Thomson⁴


¹Department of Surgery, ²Department of Radiation Oncology, ³Department of Medical Physics, University College London, UK; ⁴Photoelectron Corporation, Lexington, Massachusetts, USA

TARGIT- A randomised trial

Can risk-adapted single-dose TARGIT-IORT during lumpectomy for breast cancer effectively replace the 3-6 weeks' course of daily post-operative whole breast radiotherapy?

Recruitment: March 2000 – July 2012

www.targit.org.uk



*20% will be recommended EBRT as well

The publication of first results July 2010

Lancet 2010; 376: 91–102

2010

Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial

Jayant S Vaidya, David J Joseph, Jeffrey S Tobias, Max Bulsara, Frederik Wenz, Christobel Saunders, Michael Alvarado, Henrik L Flyger, Samuele Massarut, Wolfgang Eiermann, Mohammed Keshtgar, John Dewar, Uta Kraus-Tiefenbacher, Marc Sütterlin, Laura Esserman, Helle M R Holtveg, Mario Roncadin, Steffi Pigorsch, Marinos Metaxas, Mary Falzon, April Matthews, Tammy Corica, Norman R Williams, Michael Baum

THE LANCET Articles

Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial



2013 11 Nov 2013 Jayant S Vaidya, Frederik Wenz, Max Bulsara, Jeffrey S Tobias, David J Joseph, Mohammed Keshtgar, Henrik L Flyger, Samuele Massarut,

Michael Alvarado, Christobel Saunders, Wolfgang Eiermann, Marinos Metaxas, Elena Sperk, Marc Sütterlin, Douglas Brown, Laura Esserman, Mario Roncadin, Alastair Thompson, John A Dewar, Helle M R Holtveg, Steffi Pigorsch, Mary Falzon, Eleanor Harris, April Matthews, Chris Brew-Graves, Ingrid Potyka, Tammy Corica, Norman R Williams, Michael Baum, on behalf of the TARGIT trialists' group

Summary

Background The TARGIT-A trial compared risk-adapted radiotherapy using single-dose targeted intraoperative Lancet 2014; 383: 603-13 radiotherapy (TARGIT) versus fractionated external beam radiotherapy (EBRT) for breast cancer. We report 5-year Published Online

Breast cancer has a long natural history So, long-term outcomes are important

The first patient randomised- 24 Mar 2000Data lock for long-term outcomes -3 Jul 2019

Follow up was considered complete only if

• 95% patients had at least 5-year complete follow up

AND

 90% patients had either 10-year follow up or had been seen within previous year




Teams from all over the world helped to bring the completeness of follow-up data to 95%




The SITU team at UCL



After follow up was complete, the database was unblinded



TARGIT-A has the largest amount of follow up data amongst Partial Breast Irradiation (PBI) trials for *invasive* breast cancer



Breast cancer patients eligible for breast conserving surgery

>= 45 years, with unifocal invasive duct carcinoma

• Tumour size preferably < 3.5cm (MRI not required)

Randomisation

TARGIT

Single dose TARGIT-IORT with Intrabeam during lumpectomy, under the same anaesthetic Risk-adapted radiotherapy: EBRT added if high risk factors

found later (in ~20%)

Multiple daily doses of radiation over 3-6 weeks

EBRT

Whole breast external beam radiotherapy for every patient


Advantages of TARGIT-IORT


- Surgery and radiotherapy completed at the same time
- ✓ Less travel
- ✓ Good cosmetic outcome
- ✓ Less pain
- ✓ Fewer complications
- Lower toxicity

What is my chance of living without the cancer coming back?


Results

00







Breast cancer mortality HR 1.12 (0.78 to 1.60), P=0.54




This presentation is the intellectual property of Jayant S Vaidya. Contact jayant.vaidya@ucl.ac.uk for permission to reprint and/or distribute





Local recurrence-free survival HR 1.13 (0.91 to 1.41), P=0.28




Long-term results of the TARGIT-A trial

Breast cancer mortality HR 1.12 (0.78 to 1.60), P=0.54 Non-breast-cancer mortality HR 0.59 (0.40 to 0.86), P=0.005

Mastectomy-free survival

HR 0.96 (0.78 to 1.19), P=0.74



2000 1st patient randomised

THE LANCET

2010

"For selected patients with early breast cancer, a single dose of radiotherapy delivered at the time of surgery by use of targeted intraoperative radiotherapy should be considered as an alternative to external beam radiotherapy delivered over several weeks."

See Articles page 91

Aonitoring of neuromuscular lockade in general	CANOE: Low-dose combination therapy with	INTERSTROKE: Risk factors for ischarmic and	Diabetic retinopathy Serpage 134	Malaria in Africa since the Abuia Declaration
naesthesia mpage 77	rosiglitazone and metformin to prevent type 2 diabetes Ser page 303	intracerebral stroke Serjage 113		See page 137
	Jest Bells 213			
	per belie (sc)			

thebmj

2020

TARGIT-A long-term results: median follow-up 9 years (IQR 7-11)

- Breast cancer control comparable to EBRT
- Reduced non-breast-cancer
 mortality compared with EBRT



New treatment heralds breakthrough for breast cancer patients

50

Jill and Joe Biden

From Goldman Sachs to the yoga mat

Kat Lav Health Correspondent A single dose of radiotherany delivered from inside the body in only 30 minutes device is placed inside the breast where vival chances or the cancer returning is as effective for breast cancer as the cancer had been. Once the radioweeks of the treatment, according to a therapy dose has been delivered, the long-term study.

ball is removed and the surgical wound Doctors at University College closed up. It allows women to avoid in 2018 for centres that already had the London have developed a technique in multiple hospital visits over weeks which the therapy is given immediately for traditional radiotherapy. The new

patient is still under anaesthetic.

A small ball-shaped "Intrabeam"

after a tumour is removed, while the study, published in the BMJ, concluded cians have been waiting for longer follow-up data on patients. that there was no significant difference between the two methods in either sur-Javant Vaidva, the lead author, said that the new results should prompt The treatment, called Targeted wider use, adding: "In these terrible Intraoperative Radiotherapy (Targit times it is one good news story. There is lort), was given cautious NHS approval less nain, a better cosmetic outcome and better quality of life. "With Targit Iort, women can have equipment and trained staff, pending further results. However, many clinitheir surgery and radiation treatment

for breast cancer all at the same time This reduces the amount of time spent in hospital and enables women to re cover more quickly, meaning they can get back to their lives more quickly. "With publication of these very nositive long-term results it is now clear that this treatment should be made much more freely available. It Continued on page 2, col 3

Williamson was warned about risk of exam fiasco

Education secretary informed six weeks ago

Steven Swinford Deputy Political Editor Gavin Williamson was warned directly that the A-level and GCSE grading thousands of students being given the wrong results but decided to push

ahead, The Times can reveal. wrote to Mr Williamson early last month to express concerns about the algorithm used by Ofqual.

would be only 75 per cent accurate, meaning that hundreds of thousands of students would get the wrong grades. In found that it was 60 per cent accurate. teachers' predicted grades for small groups of nunils but leaving larger that this would lead to unfairness in the

system.

schools.

The issue proved one of the central problems as it meant that private schools, which typically can afford to system on July II in a report warning have smaller classes, saw their results that some pupils risked being "systemimprove significantly more than state atically disadvantaged by calculated

The Times understands that Mr Williamson held a video conference with Mr Coles in mid-July to discuss his arlier this week to express confidence in Sally Collier, the head of Ofqual. He concerns. He decided to push ahead bowed to pressure from his officials with the algorithm amid worries about Continued on page 2, col 3

grade inflation and the risk that results could be significantly delayed. Sir Jon, who helped to found Ofqual when he served at the Department for Educasystem could lead to hundreds of tion, did not respond to requests for comment. A government source said that the

education secretary had raised the A senior source at the Department concerns expressed by Sir Jon directly for Education disclosed that Sir Jon with Ofgual within days of the meeting Coles, a former director-general there, and had been given reassurances. The revelation that detailed concerns were put to Mr Williamson last lgorithm used by Ofqual. He said that, at best, the model being month appears at odds with his claim that the full scale of the problem with applied to A-level and GCSE grading the grading system became clear only at the weekend.

On Friday he told The Times that there would be "no U-turn" and that the event Ofqual's own tests on its algo-rithm, which were published last week, "rampant grade inflation". On Monday In his letter, Sir Jon also raised particular concerns about using of teachers' predictions and apologised to pupils, parents and schools. "Over the weekend it became clearer

groups of pupils but feating high to be the weekend to be the weekend to be the second to b getting grades that frankly they shouldn't have been getting," he said. The education select committee also

> grades Mr Williamson repeatedly refused

Teen migrant drowns as he paddles across the Channel

write the lav

Richard Ford Home Correspondent Charles Bremner Paris

A 16-year-old Sudanese migrant who could not swim drowned in the Chan nel after trying to reach Britain in a tiny makeshift boat using shovels as oars. The body of the teenager washed up on a French beach vesterday as about 150 migrants arrived in Dover after making the crossing aboard rigid hulled inflatable dinghies. A beach walker found the body after dawn at Sangatte, near the mouth of the Channel tunnel. The coastguard and police had been searching during the night after the rescue of the boy's friend also 16. The survivor, who was found suffering hypothermia at lam, said that the pair had attempted to reach England but their small craft had foundered in the waves and his friend did not know how to swim. The dead youth was identified by his friend and from his passport, which was on his body. His death was the first known to have occurred this year among the more than 4.800 migrants who have made the crossing on small craft. Last year four bodies of migrants were found in the Channel and one was

-

~~~


washed up on a French beach. About 150 migrants arrived in Kent vesterday while the French authorities escued 41 who had run into difficultie after setting sail from France.

Priti Patel, the home secretary, who has promised to make the cross Channel route "unviable", said that the death of the teenager was an upsetting and tragic loss of a young life. Sh added: "This horrendous incident serves as a brutal reminder of the abhorrent criminal gangs and neonle smugglers who exploit vulnerable

people." Marlène Schiappa, the French citizenship minister, also said that the death highlighted the need to tackle people-smugglers. She tweeted her immense sadness" at the boy's death. British and French officials will mee in Paris today to discuss how to tackle United state Jill and Joe Biden at the Democrat convention. The candidate's second wife said that he would reconcile the country as he had rebuilt his family.Page 30 France attacks'inhumane' Britain, page 3

#### Some important points!

#### **Reduced mortality with TARGIT-IORT is plausible**



#### EBRT is shown to cause cardiac perfusion defects within 6 months

### Reduced mortality with TARGIT-IORT compared with WBI is consistent with other PBI trials

Vaidya JS, Bulsara M, Wenz F, et al. Targeted radiotherapy for early breast cancer. *Lancet* 2018; **391:** 26–27.





Figure 1: Meta-analysis of mortality in six randomised trials of targeted radiotherapy

Forest plots representing meta-analysis of nearly 6000 patients in randomised trials of PBI showing the difference in mortality between PBI and WBI.

### In smokers, the increased mortality with EBRT is very high

#### Estimating the Risks of Breast Cancer Radiotherapy: Evidence From Modern Radiation Doses to the Lungs and Heart and From Previous Randomized Trials

Carolyn Taylor, Candace Correa, Frances K. Duane, Marianne C. Aznar, Stewart J. Anderson, Jonas Bergh, David Dodwell, Marianne Ewertz, Richard Gray, Reshma Jagsi, Lori Pierce, Kathleen I. Pritchard, Sandra Swain, Zhe Wang, Yaochen Wang, Tim Whelan, Richard Peto, and Paul McGale, for the Early Breast Cancer Trialists' Collaborative Group



23% smokers who have external beam radiotherapy for breast cancer will die because of heart attacks or lung cancer = A 6% increase

Giving TARGIT-IORT to smokers will reduce overall mortality by 6%

It is unethical to not offer TARGIT-IORT to eligible patients who are smokers.

6 © 2017 by American Society of Clinical Oncology

TARGIT-A had a substantial 'high-risk' population

...typical of cohort seen in our breast clinics

• 1958 (85%) patients were <=70 years

• 443 (20%) patients had grade 3 cancers

• 488 (22%) patients had involved nodes

Not 'low-risk'

Much higher risk than trials of no radiotherapy

• 426 (19%) patients had ER/PgR negative tumours

### **PRIME-2: No radiation vs WBI**

- 1326 patients. Median FU 7.3yrs
- No patients under 65 years
- 2% grade 3
- None node positive
- None ER negative
- Local control much worse than WBI 10-yr Local recurrence
   9.8% with no-radiotherapy vs 0.9% with WBI
- Was the reduction in non-BC mortality nullified by an increase in breast cancer mortality in PRIME-II?

## TARGIT-A: TARGIT-IORT during lumpectomy vs WBI

- 2298 patients. Median FU 8.6yrs
- 60% patients under 65
- 20% grade 3
- 20% node positive
- 19% ER or PgR negative
- Local control same as WBI

BC mortality same as WBI
 Significant reduction of non-breast cancer mortality reduced by 4.4% to 5.41% from 9.85% at 12 years

## **Fast-Forward**

## Whole breast irradiation

- Medium-risk patients (28%Gr3, 19% node positive)
- 7 to 15 extra visits
- BC control comparable to 3-wk EBRT
- Scattered irradiation to vital organs
   No reduction in mortality

- Higher toxicity
  - 25% patients report having a hardened/firm breast
  - Breast induration 19 times higher
     by physician assess.
- Long term follow-up not available

### **TARGIT-IORT**

## **Partial breast irradiation**

- Medium risk patients (20%Gr3, 22% node positive)
- No extra visits in 80% (15-20% WBI)
- BC control comparable to 3-wk EBRT
- No scattered irradiation to vital organs Significantly fewer cardiovascular and other cancer deaths
   9.85% reduced to 5.41% at 12 years
- Lower toxicity
- Less travel
- Better quality of life
- Less pain
- Median follow up 8.6y (max 19y)

## **Brachytherapy** (eg GEC-ESTRO)

- Low-risk patients only
- N@6 years = 784
- BC outcomes similar (5y)
- Wire entry scarring
- Additional procedure
- Lead lined walls
- 10 fractions / 5d



# **External beam PBI**

- Low-risk patients only
- N@6 years = 1915 ٠
- BC outcomes similar (10y) ۲
- Higher toxicity
- **Planning visit**
- Lead lined bunker
- 10 fractions x 5-8 d
- 15 fractions x 3 wks
- Scattered irradiation to vital organs •
- No reduction in mortality
- Scattered irradiation to vital organs
- No reduction in mortality



**TARGIT-IORT during** 

## (eg RAPID, IMPORT low) lumpectomy (TARGIT-A)

- Medium risk (20% Gr3, 22%Node pos)
- N@6 years = 1967
- BC outcomes similar(12y)
- Lower toxicity, better QOL, less pain
- No extra visits in 80%
- Routine operation theatre/room



- Delivered during initial cancer surgery
  - No scattered irradiation to vital organs
- Significant reduction in non-breast cancer deaths 9.85% reduced to 5.41% at 12y

#### **TARGIT-Retrospective** - S. Valente...... S. Grobmyer

**Conclusion:** "These data support the idea that IORT with Intrabeam is a rational option for selected patients with early stage breast cancer."

"Comparing multi center retrospective data to a prospective RTC is scientifically completely invalid, and should never be done except when naysayers are trying to support their own position of bias."

> -Dr Stephen Grobmyer -senior author of TARGIT-R paper

## TARGIT-A: TARGIT-IORT during lumpectomy vs WBI A 'real world' randomised trial – *the highest level of evidence*

- 95% complete 5-year follow up
- 90% patients seen for 10 years or in the previous year


#### Patients typical of standard breast clinic

- 66% patients <= 65
- 20% grade 3
- 22% node positive
- 19% ER / PgR negative

#### **Excellent outcomes compared to control**

- Local control same as WBI
- Distant control same as WBI
- BC mortality same as WBI





#### 2298 patients in 32 centres from 10 countries participated in the TARGIT-A trial

#### **TARGIT-A: TARGIT-IORT use in the 'real world'**





Original article

Intraoperative partial irradiation for highly selected patients with breast cancer: Results of the INTRAOBS prospective study



Claire Lemanski<sup>a</sup>, Celine Bourgier<sup>a,b</sup>, Roxanna Draghici<sup>a</sup>, Simon Thezenas<sup>c</sup>, Aurélie Morel<sup>d</sup>, Philippe Rouanet<sup>e</sup>, Pierre-Emmanuel Colombo<sup>e</sup>, Anne Mourregot<sup>e</sup>, Laure Delmond<sup>e</sup>, Pascal Fenoglietto<sup>d</sup>, Norbert Ailleres<sup>d</sup>, David Azria<sup>a,b,\*</sup>, Marian Gutowski<sup>e</sup>

<sup>a</sup> Fédération universitaire d'oncologie radiothérapie, ICM, Institut régional du cancer Montpellier, rue Croix-Verte, 34298 Montpellier cedex 05, France <sup>b</sup> IRCM, Institut de recherche en cancérologie de Montpellier, Inserm U1194, université Montpellier, avenue des Apothicaires, 34298 Montpellier cedex 05, France

<sup>c</sup> Biometrics unit, ICM-Val d'Aurelle, université Montpellier, Montpellier, France

<sup>d</sup> Radiophysics Unit, ICM-Val d'Aurelle, université Montpellier, Montpellier, France

<sup>e</sup> Department of Surgical and Reconstructive Oncology, ICM-Val d'Aurelle, université Montpellier, Montpellier, France

# 200 patients – from single-centre Montpellier, France 5-year Local recurrence 2.5%

Received: 28 June 2019 Revised: 5 August 2019 Accepted: 16 August 2019

DOI: 10.1111/tbj.13574



WILEY

SVEAST Journal

#### ORIGINAL ARTICLE

# Outcomes with intraoperative radiation therapy for early-stage breast cancer

Elizabeth Obi BS<sup>1</sup> | Martin C. Tom  $MD^1$  | Bindu V. Manyam  $MD^1$  | | Stephen R. Grobmyer  $MD^2$  | Zahraa Al-Hilli  $MD^2$  | Stephanie Valente  $MD^2$  | Alicia Fanning  $MD^2$  | Diane M. Radford  $MD^2$  | Sheen Cherian  $MD^1$  | Rahul D. Tendulkar  $MD^1$  | Chirag Shah  $MD^1$ 

<sup>1</sup>Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio

<sup>2</sup>Section of Breast Surgery, Department of Surgery, Cleveland Clinic, Cleveland, Ohio

#### Abstract

Adjuvant radiation therapy has been associated with improved local control following breast-conserving surgery. Traditionally, treatment has been delivered with whole breast irradiation over 3-6 weeks or partial breast irradiation over 1-3 weeks.

## 201 patients – in single-centre in USA 3-year Local recurrence 1.5%



ORIGINAL RESEARCH published: 08 October 2020 doi: 10.3389/fonc.2020.550327



All-inclusive!

Suitable for breast conservation with tumour **<5cm** 

No exclusions based on ER, Grade, Nodes

Targeted Intraoperative Radiotherapy Is Non-inferior to Conventional External Beam Radiotherapy in Chinese Patients With Breast Cancer: A Propensity Score Matching Study

Yin Mi<sup>1</sup>, Pengwei Lv<sup>2</sup>, Fang Wang<sup>2</sup>, Lin Li<sup>2</sup>, Mingzhi Zhu<sup>2</sup>, Yanyan Wang<sup>2</sup>, Yingying Zhang<sup>2</sup>, Lele Liu<sup>1</sup>, Qinchen Cao<sup>1</sup>, Meilian Dong<sup>1</sup>, Yonggang Shi<sup>1</sup>, Ruitai Fan<sup>1</sup>, Jingruo Li<sup>2</sup>, Yuanting Gu<sup>2</sup> and Xiaoxiao Zuo<sup>1\*</sup>

<sup>1</sup> Department of Radiation Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China, <sup>2</sup> Department of Breast Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China

82 + 199 (control) patients – in single-centre in China 5-year Local recurrence 3.2% in TARGIT-IORT v 3.1% in control

Edited by:

Francesco Cellini

**OPEN ACCESS** 

# Journal of Clinical Oncology®

An American Society of Clinical Oncology Journal

Enter words / phrases / DOI / ISBN / authors / keywords / etc.

| Newest Articles                                                             | Issues       | Special Content                                                           | Authors              | Subscribers               | About                | ASC                    | O Publications   | Career Center | COVID-19 |
|-----------------------------------------------------------------------------|--------------|---------------------------------------------------------------------------|----------------------|---------------------------|----------------------|------------------------|------------------|---------------|----------|
| Journal of Clinical Oncology > List of Issues > Volume 34, Issue 15 suppl > |              |                                                                           |                      |                           |                      |                        | OPTIONS & TOOLS  |               |          |
| BREAST CANCER-TRIPLE-NEGATIVE/CYTOTOXICS/LOCAL THERAPY                      |              |                                                                           |                      |                           |                      |                        | Export Citation  |               |          |
| Mid-term results of INTRABEAM intraoperative                                |              |                                                                           |                      |                           |                      |                        | • Track Citation |               |          |
| radiotherapy in St. Petersburg, Russia.                                     |              |                                                                           |                      |                           |                      |                        | Add To Favorites |               |          |
| Check for updates                                                           |              |                                                                           |                      |                           |                      | Ø Rights & Permissions |                  |               |          |
| <u>Alexey Manikhas, A</u><br>Roman Babeshkin,                               |              | <u>esyn</u> , <u>Ivan Grinev, Se</u><br>nikhas                            | <u>rgey Chekrizc</u> | v, <u>Vitaly Skvortso</u> | <u>v, Leonid Li,</u> |                        | f У              | <b>-</b>      |          |
| Dispensary, St. Pete                                                        | ersburg, Rus | nsary, St. Petersburg,<br>ssian Federation; City<br>I Oncology Center, St | Clinical Onco        | ology Dispensary,         |                      |                        | COMPANIO         | ON ARTICLES   |          |
| Show Less                                                                   |              |                                                                           |                      |                           |                      | No companion articles  |                  |               |          |
| Abstract Disclosure                                                         | s 🗹          |                                                                           |                      |                           |                      |                        | ARTICLE C        | ITATION       |          |
| oont                                                                        |              | ы C+                                                                      |                      |                           |                      | ~                      | Due              | aia           |          |

129 patients – from single centre in St Petersburg, Russia Follow up 3 years

- Local recurrence 1.5%
- They have now treated over 1200 patients

International Journal of ASTRO Radiation Oncology • Biology • Physics

Register Subscribe Log in Claim

 $\bigcirc$ 

#### **Real world data** D PDF å **F** ORAL SCIENTIFIC SESSION | VOLUME 105, ISSUE 1, SUPPLEMENT, S8, SEPTEMBER 01, 2019 PDF [254 KB] Save Share Reprints Request First per Protocol Analysis of the Prospective Phase II Study of Intraoperative Radiotherapy (IORT) in Elderly Patients with Small Breast Cancer: Targit E(Iderly) E. Sperk PROSPECTIVE PlumX Metrics DOI: https://doi.org/10.1016/j.ijrobp.2019.06.393 Check for updates **Real-World study**

541 patients – 28 centres in Germany, France, Denmark, Switzerland

- 5-year Local recurrence 1.5%
- 5-year Overall survival 91.4%

| Received: 25 February 2020 | Revised: 11 March 2020 | Accepted: 11 March 2020 |
|----------------------------|------------------------|-------------------------|
|                            | 2                      |                         |

DOI: 10.1111/tbj.13827



updates

ORIGINAL ARTICLE

The actual benefit of intraoperative radiation therapy using 50 kV x-rays in early breast cancer: A retrospective study of 676 patients

| Agnès Tallet MD <sup>1,2</sup> 💿 📔 Séverine Racadot MD <sup>3</sup> 📔 Jean-Marie Boher PhD <sup>4,5</sup> 🛛      |
|------------------------------------------------------------------------------------------------------------------|
| Monique Cohen MD <sup>6</sup>   Julien Barrou MD <sup>5,6</sup>   Gilles Houvenaeghel MD, PhD <sup>2,5,6</sup> 💿 |
| Marian Gutowski MD <sup>7</sup>   Laure Delmond MD <sup>7</sup>   Claire Lemanski MD <sup>8</sup>                |

676 patients – from 3 centres in France
Median follow up 54 months
5-year Local recurrence 1.7% (11 local recurrences)
5-year Overall survival 96.5%

Hindawi Publishing Corporation International Journal of Breast Cancer Volume 2014, Article ID 637898, 6 pages http://dx.doi.org/10.1155/2014/637898



#### **Review** Article

#### **Intraoperative Boost Radiotherapy during Targeted Oncoplastic Breast Surgery: Overview and Single Center Experiences**

Wolfram Malter,<sup>1</sup> Verena Kirn,<sup>1,2</sup> Lisa Richters,<sup>1,2</sup> Claudius Fridrich,<sup>1,2</sup> Birgid Markiefka,<sup>3</sup> Rudolf Bongartz,<sup>4</sup> Robert Semrau,<sup>4</sup> Peter Mallmann,<sup>2</sup> and Stefan Kraemer<sup>1</sup>

<sup>1</sup>Breast Center, University Hospital of Cologne, Kerpenerstrasse 34, 50931 Cologne, Germany
 <sup>2</sup>Department of Obstetrics and Gynaecology, University Hospital of Cologne, Kerpenerstrasse 34, 50931 Cologne, Germany
 <sup>3</sup>Department of Pathology, University Hospital of Cologne, Kerpenerstrasse 34, 50931 Cologne, Germany
 <sup>4</sup>Department of Radiotherapy, University Hospital of Cologne, Kerpenerstrasse 34, 50931 Cologne, Germany

149 patients – excellent results



FIGURE 1: Combination of IORT boost irradiation with targeted oncoplastic breast-conserving surgery (dermoglandular rotation).

TARGIT-IORT during oncoplastic surgery will ensure high precision and immediacy of radiotherapy Strahlenther Onkol (2017) 193:62–69 DOI 10.1007/s00066-016-1072-y




ORIGINAL ARTICLE

### Targeted intraoperative radiotherapy tumour bed boost during breast-conserving surgery after neoadjuvant chemotherapy

Hans-Christian Kolberg<sup>1</sup> · Gyoergy Loevey<sup>2</sup> · Leyla Akpolat-Basci<sup>1</sup> · Miltiades Stephanou<sup>1</sup> · Peter A Fasching<sup>3</sup> · Michael Untch<sup>4</sup> · Cornelia Liedtke<sup>5</sup> · Max Bulsara<sup>6,7</sup> · Jayant S Vaidya<sup>7</sup>











Fig. 1 Local recurrence-free survival, disease-free survival and distant disease-free survival (*TARGIT* targeted intraoperative radiotherapy boost; *EBRT* external beam radiotherapy boost)







**Fig. 2** Overall survival, breast cancer deaths and non-breast cancer deaths (*TARGIT* targeted intraoperative radiotherapy boost, *EBRT* external beam radiotherapy boost)

TARGIT-IORT Boost after neoadjuvant chemotherapy and oncoplastic surgery seems to improve oncological and survival outcomes

TARGIT-B trial for young veryhigh-risk patients currently recruiting in China, S Korea, S Aftrica, Middle-East,Europe, USA

# Conclusions

### Long-term outcomes of the TARGIT-A Trial

#### Risk-adapted TARGIT-IORT given during lumpectomy

- achieved comparable long-term cancer control to EBRT
- reduced non-breast-cancer mortality compared with EBRT

#### TARGIT-IORT has substantial advantages:

- o better quality of life, cosmetically superior, less pain
- o more convenient for the patient, less travel time
- o lower cost to the patient and healthcare system

Eligible patients should be offered TARGIT-IORT as a one-stop treatment option during their lumpectomy for breast cancer

# UK NICE recommends TARGIT IORT

#### in centres which have the equipment and expertise

women found

quicker and

#### THE MARTIMES **Health News**

News Opinion Business Money Sport Life Arts Puzzles Papers

Single-dose radiotherapy eases breast cancer stress




jobs more - UK edition -Q search theguardian home world sport football opinion culture economy lifestyle fash = all

#### **Breast cancer**

#### Single-dose radiotherapy could transform breast cancer treatment

Intrabeam radiotherapy, which has go-ahead for NHS use, is given during surgery, eliminating need for additional hospital trips





NEWS VIDEO PEOPLE VOICES SPORT TECH LIFE PROPERTY ARTS+ENTS TRAVEL MON

Fashion \* / Food and Drink \* / Health & Families \* / History / Gadgets and Tech \* / Motoring \* / Dating \* / Crossword

Life > Health & Families > Health News

#### NHS approves one-shot breast cancer therapy troatmont



#### 15/02/2017

We've recommended the Intrabeam Radiotherapy System for people with early breast cancer: nice.org.uk/news/article/n...







Home News U.S. Sport TV&Showbiz Australia Femail Health Science Money





Half-hour breast cancer treatment can replace weeks of radiotherapy: Thousands of women could benefit from treatment

 Intrabeam radiotherapy will be given to breast cancer patients in surgery Treatment has been given provisional go-ahead for use on NHS by NICE Up to 36,000 women with early breast cancer could benefit from technique

By JENNY HOPE FOR THE DAILY MAIL PUBLISHED: 23:03. 24 July 2014 | UPDATED: 13:53. 25 July 2014





Chris Smyth Health Correspondent Last updated at 12:01AM, July 25 2014

# 2016 1<sup>st</sup> US user meeting



# 2016 Mannheim user meeting



# Dec 2016 Bangkok user meeting



# May 2017 1st US TARGIT collaborative group



# 2018 Mannheim user meeting



# Over 250 centres in 38 countries have offered TARGIT-IORT for breast cancer



+

\*Data from 260 centres (updated late 2019- early 20)



TARGIT-IORT has now been used in >45,000 women around the world

# It should be available to every suitable patient

**THANK YOU** 

More info at targit.org.uk

